Immune-Mediated Necrotizing Myopathy
Neurology
Prevalence
5.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
Frequently asked questions
How many drugs are in development for Immune-Mediated Necrotizing Myopathy?
BioSniper tracks 1 drug in development for Immune-Mediated Necrotizing Myopathy across 1 company.
How many clinical trials target Immune-Mediated Necrotizing Myopathy?
There are 2 clinical trials targeting Immune-Mediated Necrotizing Myopathy tracked by BioSniper.
What is the prevalence of Immune-Mediated Necrotizing Myopathy?
The estimated prevalence of Immune-Mediated Necrotizing Myopathy is approximately 5.0 per 100,000 population.
Deep-dive into Immune-Mediated Necrotizing Myopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis